Oxbryta - (300 mg and 500 mg ; Tablet)

Generic Name	Voxelotor	Innovator	Global Blood Theraps
Dosage	300 mg and 500 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*** ****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
***** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events

Oxbryta - (300 mg ; Tablets for Oral Suspension)

Generic Name	Voxelotor	Innovator	Global Blood Theraps
Dosage	300 mg ; Tablets for Oral Suspension	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
***** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events